<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 15, 2018 (HealthDay News) — Maternal use of \u03b2-blockers in the first trimester of pregnancy is not associated with a large increase in the risk for overall or cardiac congenital malformations, according to a study published online Oct. 16 in the Annals of Internal Medicine<\/i>.<\/p>\n
Brian T. Bateman, M.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues estimated the risks for major congenital malformations associated with first-trimester exposure to \u03b2-blockers using data from health registries in the five Nordic countries and the U.S. Medicaid database.<\/p>\n
The researchers found that the \u03b2-blocker-associated pooled adjusted relative risk (RR) and risk difference per 1,000 persons exposed (RD1000<\/sub>) were 1.07 (95 percent confidence interval, 0.89 to 1.3) and 3 (confidence interval, \u22126.6 to 12.6) for any major malformation; 1.12 (95 percent confidence interval, 0.83 to 1.51) and 2.1 (confidence interval, \u22124.3 to 8.4) for any cardiac malformation; and 1.97 (95 percent confidence interval, 0.74 to 5.25) and 1 (confidence interval, \u22120.9 to 3) for cleft lip or palate. Based on the U.S. cohort data only, the adjusted RR and RD1000<\/sub> were 1.37 (95 percent confidence interval, 0.58 to 3.25) and 1 (confidence interval, \u22122 to 4) for central nervous system malformations.<\/p>\n “The potential risks to the fetus must be balanced against the risks to the mother associated with untreated hypertension,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n